Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
3期
已完成
NCT01282073
| 适应症 | Glomerulonephritis, Membranous |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Kyungpook National University Hospital |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 43 人 |
|---|
| 干预（药物） | Mycophenolate mofetil, low dose steroid, Cyclosporin, low dose steroid |
|---|
| 开始日期 | 2011年3月 |
|---|
| 完成日期 | 2016年5月 |
|---|
| 结果公布日 | 2025年8月27日 |
|---|
摘要
Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.
Percentage of Complete Remission
at 48 week after treatment · Participants
| Mycophenolate Mofetil, Low Dose Steroid | 4 Participants |
|---|
| Cyclosporin, Low Dose Steroid | 3 Participants |
|---|
Percentage of Partial Remission
at 48 week after treatment · Participants
| Mycophenolate Mofetil, Low Dose Steroid | 12 Participants |
|---|
| Cyclosporin, Low Dose Steroid | 9 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。